Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy.

Area of Science:

• Pharmaceutics and Drug Design
• Bioinformatics
• Nanomedicine

Background:

• Peptide-based therapeutics historically faced challenges with low selectivity and rapid degradation.
• Recent advancements in bioinformatics and drug delivery systems are revitalizing interest in peptide-based drugs.
• Anticancer therapies are a key focus, demanding targeted effects and reduced toxicity.

Purpose of the Study:

• To review the evolution and current trends in amino acid-based drug design.
• To highlight novel peptide-based therapeutics and drug delivery systems.
• To provide insights into rational drug design for future pharmaceutical applications.

Main Methods:

• Literature review of recent advancements in peptide and protein bioinformatics.
• Analysis of emerging drug delivery systems including nanomedicine and antibody-drug conjugates (ADC).
• Examination of peptide-drug conjugates (PDC), peptide-based nanoparticles, and prodrugs.

Main Results:

• Peptide-based drug design has overcome previous physiological limitations.
• Nanomedicine and ADC have significantly improved therapeutic efficacy.
• Novel formulations like PDCs and peptide nanoparticles show promising therapeutic strategies.

Conclusions:

• Amino acid-based drug design is a rapidly advancing field with significant pharmaceutical potential.
• Targeted drug delivery systems are crucial for enhancing the efficacy and safety of peptide therapeutics.
• Future research should focus on rational design for developing effective peptide-based treatments.